Evidence map›Paper›PMID 19331850›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2009

Digoxigenin modification of adenovirus to spatially control gene delivery from chitosan surfaces.

Wei-Wen Hu, Michael W Lang, Paul H Krebsbach

Abstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Scaffold-mediated lentiviral transduction for functional tissue engineering of cartilage.Proceedings of the National Academy of Sciences of the United States of America · 2014
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Wei-Wen HuDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Michael W Lang
Paul H Krebsbach
University of Michigan–Ann Arbor · US

Funding

Engineering Multi-Tissue InterfacesR01DE018890 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KREBSBACH, PAUL HUGO · 2008 to 2012
$1.8M
NIDCR NIH HHS R01 DE018890
6 · The paper itself

Abstract

To spatially control the delivery of multiple viral vectors from biomaterial scaffolds, digoxigenin (DIG) was conjugated to adenoviral capsid proteins as an antigenic determinant for antibody immobilization. The infectivity, toxicity, specificity and immobilization stability of DIG-modified adenovirus were examined to investigate the feasibility and effectiveness of this viral surface modification. Anti-DIG antibody conjugated on chitosan surfaces was able to immobilize DIG-modified adenovirus and could be stably bound on the material for at least two weeks, yet the modification was mild enough that viral infectivity was maintained. To immobilize two different adenoviruses, wax masking was applied to conjugate anti-DIG and anti-adenovirus antibodies in two discrete regions of a chitosan film. The distribution of these two viral vectors expressing different reporter genes was examined after cell culture. Fluorescent protein expression from transduced cells illustrated that the infection distribution could be controlled: one gene was delivered to the entire region of the biomaterial, and another was only delivered to defined regions. Compared to three other cardiac glycosides, ATPase inhibition was undetectable when DIG was conjugated on the adenovirus, suggesting that the method may be safe for in vivo application. This dual viral vector delivery system should be capable of generating distinct interfaces between cell signaling viruses to control tissue regeneration from a range of different biomaterials.

Indexed as

Genetic VectorsGene Transfer TechniquesAdenoviridaeAntibodies, ImmobilizedAntibodies, ViralCapsid ProteinsChitosanCoated Materials, BiocompatibleDigoxigeninHumansModels, GeneticTime FactorsTissue ScaffoldsTransduction, GeneticAntibodies, ImmobilizedAntibodies, ViralCapsid ProteinsChitosanCoated Materials, BiocompatibleDigoxigenin

Identifiers

PMID19331850
PMCPMC2668726
OpenAlexW1986603025

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.